Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Shares Outstanding (Diluted Average): 2023-2025

Historic Shares Outstanding (Diluted Average) for Monte Rosa Therapeutics (GLUE) over the last 3 years, with Sep 2025 value amounting to $82.9 million.

  • Monte Rosa Therapeutics' Shares Outstanding (Diluted Average) rose 1.14% to $82.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.9 million, marking a year-over-year increase of 1.14%. This contributed to the annual value of $73.9 million for FY2024, which is 43.80% up from last year.
  • According to the latest figures from Q3 2025, Monte Rosa Therapeutics' Shares Outstanding (Diluted Average) is $82.9 million, which was up 0.06% from $82.9 million recorded in Q2 2025.
  • Monte Rosa Therapeutics' Shares Outstanding (Diluted Average)'s 5-year high stood at $83.0 million during Q1 2025, with a 5-year trough of $49.3 million in Q1 2023.
  • Its 3-year average for Shares Outstanding (Diluted Average) is $66.9 million, with a median of $71.2 million in 2024.
  • Data for Monte Rosa Therapeutics' Shares Outstanding (Diluted Average) shows a peak YoY skyrocketed of 64.63% (in 2024) over the last 5 years.
  • Monte Rosa Therapeutics' Shares Outstanding (Diluted Average) (Quarterly) stood at $51.4 million in 2023, then soared by 43.80% to $73.9 million in 2024, then climbed by 1.14% to $82.9 million in 2025.
  • Its Shares Outstanding (Diluted Average) was $82.9 million in Q3 2025, compared to $82.9 million in Q2 2025 and $83.0 million in Q1 2025.